Ovestin (Estriol)

Ovestin is an estrogen preparation that acts on the hormonal pathways involved in menopause and related conditions.

• Menopausal vasomotor symptoms: Reduces frequency and severity of hot flashes.
• Genitourinary syndrome of menopause: Improves vaginal dryness and discomfort.
• Osteopenia prevention: Contributes to maintenance of bone mineral density.
• Hypo‑estrogenic states caused by ovarian failure: Restores systemic estrogen activity.

• Estradiol binds to estrogen receptors α and β in target tissues, initiating transcription of estrogen‑responsive genes. This receptor activation modulates the hypothalamic‑pituitary‑gonadal axis, influences calcium metabolism, and promotes proliferation of vaginal and uterine epithelium, producing systemic estrogenic effects.

Side effects associated with estrogen therapy vary in frequency and severity.

Common Side Effects

• Nausea: Mild, transient gastrointestinal upset.
• Breast tenderness: Localized discomfort or swelling.
• Headache: Tension‑type or mild migraine‑like pain.
• Fluid retention: Mild peripheral edema.
• Mood changes: Irritability or mild depressive symptoms.

Serious or Rare Side Effects

• Venous thromboembolism: Deep‑vein thrombosis or pulmonary embolism.
• Stroke: Ischemic or hemorrhagic cerebrovascular event.
• Endometrial hyperplasia: Abnormal thickening of the uterine lining.
• Hepatotoxicity: Elevated liver enzymes or hepatic dysfunction.
• Carcinoma risk: Potential increase in breast or endometrial cancer incidence.

When prescribing Ovestin, clinicians should evaluate individual risk factors and monitor therapy closely.

• Cardiovascular risk assessment: Review history of thromboembolic events, hypertension, or smoking.
• Cancer surveillance: Monitor for signs of breast, uterine or ovarian malignancy.
• Liver function monitoring: Check baseline and periodic liver enzymes.
• Bone health evaluation: Assess bone mineral density in long‑term users.
• Drug‑interaction review: Verify concomitant medications that affect estrogen metabolism.
• Store at ambient temperature: Keep below 25 °C, in the original container, protected from moisture and light.

Estradiol may interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Combined oral contraceptives: Increases risk of thromboembolic events.
• Anticoagulants (warfarin, DOACs): May potentiate anticoagulant effect and bleeding.
• Hepatotoxic drugs (isoniazid, ketoconazole): Heighten risk of liver injury.

Moderate Interactions (Monitor Closely)

• Antidepressants (SSRIs, SNRIs): May reduce estradiol metabolism, raising plasma levels.
• Antiepileptics (phenytoin, carbamazepine): May increase estradiol clearance, lowering efficacy.
• Herbal supplements (St. John’s wort): May induce hepatic enzymes and decrease estradiol exposure.